Regeneron’s Libtayo/Fianlimab LAGs Bristol’s Opdualag On Timing, But May Win On Efficacy

Company Looks At Coformulation

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.